{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T21:51:47Z","timestamp":1765057907108,"version":"build-2065373602"},"reference-count":48,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jcyt.2025.03.002","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T12:50:46Z","timestamp":1741783846000},"page":"733-743","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Center effect on outcomes of second allogeneic hematopoietic stem cell transplantation for B-cell acute lymphoblastic leukemia: a nationwide retrospective study"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6426-6770","authenticated-orcid":false,"given":"Shuhei","family":"Kurosawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuo","family":"Ichinohe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1668-274X","authenticated-orcid":false,"given":"Yoshiko","family":"Hashii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6704-3633","authenticated-orcid":false,"given":"Junya","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7668-6083","authenticated-orcid":false,"given":"Fumihiko","family":"Ishimaru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5935-0385","authenticated-orcid":false,"given":"Makoto","family":"Yoshimitsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moeko","family":"Hino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keitaro","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsumi","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3522-2278","authenticated-orcid":false,"given":"Marie","family":"Ohbiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Tabuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2025.03.002_bib0001","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/hematology.2024000532","article-title":"Ph+ ALL: new approaches for upfront therapy","volume":"2024","author":"Luskin","year":"2024","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0002","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1182\/hematology.2024000531","article-title":"Ph-ALL: immunotherapy in upfront treatment","volume":"2024","author":"Stelljes","year":"2024","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0003","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/bloodadvances.2021004607","article-title":"Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"6","author":"Sugiura","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0004","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2013-11-538728","article-title":"Pretransplant administration of imatinib for allo-HSCT in patients with BCR-ABL-positive acute lymphoblastic leukemia","volume":"123","author":"Mizuta","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0005","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1038\/bcj.2014.72","article-title":"Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group","volume":"4","author":"Hayakawa","year":"2014","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0006","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/leu.2017.283","article-title":"High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: a phase III study by JALSG","volume":"32","author":"Sakura","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0007","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab Ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0008","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0009","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0010","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1182\/hematology.2024000533","article-title":"Transplant in ALL: who, when, and how?","volume":"2024","author":"Marcoux","year":"2024","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0011","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/ajh.24933","article-title":"Improved prognosis with additional medium-dose VP16 to CY\/TBI in allogeneic transplantation for high risk ALL in adults","volume":"93","author":"Arai","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0012","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1182\/bloodadvances.2022008032","article-title":"Improvements in allogeneic hematopoietic cell transplantation outcomes for adults with ALL over the past 3 decades","volume":"6","author":"Nishiwaki","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0013","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s12185-021-03198-4","article-title":"Optimal treatment for Philadelphia-negative acute lymphoblastic leukemia in first remission in the era of high-intensity chemotherapy","volume":"114","author":"Kako","year":"2021","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0014","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.jcyt.2022.03.004","article-title":"Overcoming minimal residual disease using intensified conditioning with medium-dose etoposide, cyclophosphamide and total body irradiation in allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults","volume":"24","author":"Harada","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0015","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1182\/blood-2004-10-3863","article-title":"Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United States","volume":"105","author":"Loberiza","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0016","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/sj.bmt.1702681","article-title":"Hospital capacity and post-transplant survival after allogeneic bone marrow transplantation: analysis of data from the Japan Society for Hematopoietic Cell Transplantation","volume":"26","author":"Matsuo","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0017","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1182\/blood-2009-03-207001","volume":"115","author":"Klingebiel","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0018","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1097\/HS9.0000000000000810","article-title":"Impact of center-related characteristics and macroeconomic factors on the outcome of adult patients with acute lymphoblastic leukemia treated with pediatric-inspired protocols","volume":"7","author":"Barba","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0019","doi-asserted-by":"crossref","first-page":"326.e1","DOI":"10.1016\/j.jtct.2024.01.056","article-title":"Impact of center volume on chronic graft versus host disease in patients with allogeneic stem cell transplantation","volume":"30","author":"Shimomura","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0020","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41409-024-02222-5","article-title":"The effect of center experience on allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia","volume":"59","author":"Yanada","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0021","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.bbmt.2015.10.006","article-title":"Comparison of outcomes of 8\/8 and 7\/8 allele-matched unrelated bone marrow transplantation and single-unit cord blood transplantation in adults with acute leukemia","volume":"22","author":"Terakura","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0022","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41375-019-0534-5","article-title":"Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord\/ALWP-EBMT and JSHCT\/JDCHCT collaborative study","volume":"34","author":"Kanda","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0023","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.jcyt.2024.05.004","article-title":"Center effect on allogeneic hematopoietic stem cell transplantation outcomes for B-cell acute lymphoblastic leukemia","volume":"26","author":"Kurosawa","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0024","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12185-015-1894-x","article-title":"Introduction of transplant registry unified management program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data)","volume":"103","author":"Atsuta","year":"2016","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12185-015-1907-9","article-title":"Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation","volume":"103","author":"Kanda","year":"2016","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0026","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41409-021-01310-0","article-title":"Prognostic factors in salvage transplantation for graft failure following allogeneic hematopoietic stem cell transplantation","volume":"56","author":"Harada","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0027","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41409-024-02251-0","article-title":"Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT","volume":"59","author":"Sureda","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0028","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0029","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0030","doi-asserted-by":"crossref","first-page":"326.e1","DOI":"10.1016\/j.jtct.2022.03.017","article-title":"Allogeneic hematopoietic stem cell transplantation for adult Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in second complete remission","volume":"28","author":"Kaito","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0031","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.3324\/haematol.2019.220756","volume":"105","author":"Lazaryan","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0032","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/blood-2006-10-051912","article-title":"Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII\/Eastern Cooperative Oncology Group (ECOG) 2993 trial","volume":"109","author":"Moorman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0033","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","article-title":"Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research","volume":"15","author":"Giralt","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0034","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1007\/s00277-021-04661-2","article-title":"The differential effect of disease status at allogeneic hematopoietic cell transplantation on outcomes in acute myeloid and lymphoblastic leukemia","volume":"100","author":"Yanada","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0035","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1200\/JCO.2011.38.7589","article-title":"Missing data in clinical studies: issues and methods","volume":"30","author":"Ibrahim","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0036","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0037","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/bmt.2012.195","article-title":"Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia","volume":"48","author":"Poon","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0038","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1038\/s41409-021-01317-7","article-title":"Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT","volume":"56","author":"Kharfan-Dabaja","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0039","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/bjh.15973","article-title":"Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"186","author":"Nagler","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0040","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s12185-022-03377-x","article-title":"Outcomes in patients with acute lymphoblastic leukemia who underwent second allogeneic hematopoietic cell transplantation for relapse after first transplantation","volume":"116","author":"Tachibana","year":"2022","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0041","first-page":"2767","article-title":"Feasibility and usefulness of recommended screenings at long-term follow-up clinics for hematopoietic cell transplant survivors","volume":"30","author":"Kurosawa","year":"2022","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0042","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.bbmt.2020.01.008","article-title":"Current status and needs of long-term follow-up clinics for hematopoietic cell transplantation survivors: results of a nationwide survey in Japan","volume":"26","author":"Kurosawa","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0043","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.bbmt.2009.06.017","article-title":"Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia","volume":"15","author":"Liu","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0044","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood-2011-01-330217","article-title":"Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation","volume":"118","author":"Inamoto","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0045","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/s41409-024-02302-6","article-title":"Feasibility and safety of the discontinuation of systemic immunosuppressive treatment after single-unit cord blood transplantation in adults","volume":"59","author":"Konuma","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0046","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1047554","article-title":"Immunophenotypic measurable residual disease monitoring in adult acute lymphoblastic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Tecchio","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0047","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1182\/blood.2021011921","article-title":"Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1\/2 mutations","volume":"139","author":"Yasuda","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.03.002_bib0048","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1182\/bloodadvances.2019000163","article-title":"Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"4","author":"Harvey","year":"2020","journal-title":"Blood Adv"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925000714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925000714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:09:51Z","timestamp":1762546191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324925000714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1465324925000714"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.03.002","relation":{},"ISSN":["1465-3249"],"issn-type":[{"type":"print","value":"1465-3249"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Center effect on outcomes of second allogeneic hematopoietic stem cell transplantation for B-cell acute lymphoblastic leukemia: a nationwide retrospective study","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}